Product Description
For chronic stable heart failure
Mechanisms of Action: APJ Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Failure, Chronic|Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CCLR325X2202 | P2 |
Completed |
Heart Failure |
2019-01-14 |
|
CCLR325X2202 | P2 |
Completed |
Heart Failure, Chronic |
2019-01-14 |